Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical study
commissioner
crispr
democrats
2
×
detroit blog main
detroit top stories
failure
fda
gene editing
glaxosmithkline
ipo
life sciences
national
national blog main
national top stories
new york blog main
2
×
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
scott gottlieb
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
2025
ad-comm
advaxis
affimed
aimmune therapeutics
What
bio
crispr
2
×
roundup
allogene
big
bosley's
bosley’s
bridge
bucks
cancer
cas
ceo
crime
departure
diversity
editas
exit
guiding
hot
immunotherapy
investors
ipo
juno
katrine
medicine
million
moves
nearly
new
personnel
remains
shares
snapped
surprising
therapeutics
ticket
utero
week
years
Language
Current search:
crispr
×
democrats
×
" new york blog main "
×
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
Bio Roundup: BIO Diversity, Allogene IPO, CRISPR In Utero & More